Arun J. Sanyal

Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH.

The global cardiovascular-liver-metabolic syndemic: epidemiology, trends and challenges.

MicroRNA isomiRs reveal novel pathways linked to disease activity and fibrosis in MASLD

Glucagon-like Peptide-1 Receptor Agonists Improve Liver and Metabolic Health Outcomes in Type 2 Diabetes and Obesity Regardless of Prior Liver Disease

Disease-driven loss of inactive HSD17B13 isoforms enhances enzymatic output in MASH and counters protective rs72613567:TA variant.

Lower Health Literacy Is Associated With Greater Severity of Metabolic Dysfunction and Steatotic Liver Disease.

Fibroblast Growth Factor 21: Mechanisms, Therapeutic Potential, and Clinical Translation in Metabolic Dysfunction.

A reasonably likely surrogate endpoint for metabolic dysfunction-associated steatohepatitis.

MASLD as a complication of obesity must include liver risk stratification.

Multi-threshold analysis of the ELF Test versus histology for prognostication of disease progression and regression in MASH.

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Association of Components of Metabolic Syndrome and the Progression of Nonalcoholic Fatty Liver Disease.

Prevalence, Trends, and Mortality of Low Muscle Mass and Its Association With Metabolic Diseases in the United States Population

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association

ECM formation and degradation during fibrosis, repair, and regeneration

Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (<scp>MASLD</scp>) and Metabolic Dysfunction‐Associated Steatohepatitis (<scp>MASH</scp>): From the Growing Prevalence to Payors' Perspective

Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease

Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis

Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD

Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective.

Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis

Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis.

Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology.

From “Burnt-Out” to “Burning-Out”: Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction–Associated Steatotic Liver Disease From a Dynamic Perspective

Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the <scp>SURMOUNT</scp> ‐ <scp>MMO</scp> trial

Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis.

Cardiac and liver impairment on multiorgan MRI and risk of major adverse cardiovascular and liver events

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD

Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease